Drug: CDX-110 (PF-04948568)
Abstract No.2014Indication: Glioblastoma (brain tumor) Clinical Trial: Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide in patients with glioblastoma (GBM). Presentation Time: Saturday, June 5. Poster session. Notes: Celldex's CDX-110, partnered with Pfizer, is engineered to activate a patient's immune system to fight cancer. Interest in so-called cancer "vaccines" is increasing as Dendreon (DNDN) awaits FDA approval of its prostate cancer immunotherapy Provenge. Celldex shares are running strong into the ASCO meeting, up 60% since February.